Table 2 Patient Characteristics
From: Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia
| Â | All (n = 103) | Treatment Failure (n = 42) | No Treatment Failure (n = 61) |
|---|---|---|---|
Age, year, mean (SD) | 51 (14.1) | 51 (14.3) | 51 (14.0) |
Female, No. (%) | 62 (60.2) | 24 (57.1) | 38 (62.3) |
Nonwhite, No. (%) | 5 (4.9) | 4 (9.5) | 1 (1.6) |
Uninsured or Medicaid, No. (%) | 12 (11.7) | 6 (14.3) | 6 (9.8) |
Primary diagnosis, No. (%) | Â | Â | Â |
   Hematological malignancies | 79 (76.7) | 38 (90.5) | 41 (67.2) ‡ |
Acute leukemia/MDS | 40 (38.8) | 20 (47.6) | 20 (32.8) |
Chronic leukemia | 7 (6.8) | 3 (7.1) | 4 (6.6) |
Lymphoma | 23 (22.3) | 11 (26.2) | 12 (19.7) |
Myeloma | 5 (4.9) | 3 (7.1) | 2 (3.3) |
Hodgkin's disease | 4 (3.9) | 1 (2.4) | 3 (4.9) |
   Solid tumors | 24 (23.3) | 4 (9.5) | 20 (32.8) |
Underlying disease, No. (%) | 11 (10.7) | 5 (11.9) | 6 (9.8) |
   Cardiovascular disease | 4 (3.9) | 2 (4.8) | 2 (3.3) |
   Others * | 7 (6.8) | 3 (7.1) | 4 (6.6) |
DRG weight, mean (SD) | 7.4 (3.7) | 7.0 (3.6) | 7.7 (3.7) |
Charlson score, mean (SD) | 3.0 (1.7) | 2.6 (1.4) | 3.3 (1.8) ‡ |
Charlson score ≤ 4, No. (%) | 80 (77.7) | 38 (90.5) | 42 (68.9) ‡ |
Treatment before fluconazole started, No. (%) | |||
   Steroid | 17 (16.5) | 7 (16.7) | 10 (16.4) |
   Chemotherapy | 98 (95.2) | 38 (90.5) | 60 (98.4) |
   Cyclosporin | 6 (5.8) | 3 (7.1) | 3 (4.9) |
History of Transplant, No. (%) | |||
   Bone marrow transplant | 56 (54.4) | 23 (54.7) | 33 (54.1) |
Lab results before fluconazole started, No. (%) | |||
   ANC ≤ 100/mm3 | 74 (71.8) | 33 (78.6) | 41 (67.2) |
   Positive fungal cultures ** | 19 (18.5) | 9 (21.4) | 10 (16.4) |
Candida albicans | 15 (14.6) | 8 (19.1) | 7 (11.5) |
Yeast species | 7 (6.8) | 3 (7.1) | 4 (6.6) |
Duration before fluconazole started, day, mean (SD) | |||
   Fever | 7.9 (6.8) | 7.5 (6.9) | 8.3 (6.8) |
   Neutropenia | 6.5 (6.9) | 6.5 (6.8) | 6.4 (7.0) |
Deceased, No. (%) | 8 (7.8) | 6 (14.3) | 2 (3.3) †|